These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
219 related articles for article (PubMed ID: 36248870)
1. Peripheral blood marker of residual acute leukemia after hematopoietic cell transplantation using multi-plex digital droplet PCR. Stanojevic M; Grant M; Vesely SK; Knoblach S; Kanakry CG; Nazarian J; Panditharatna E; Panchapakesan K; Gress RE; Holter-Chakrabarty J; Williams KM Front Immunol; 2022; 13():999298. PubMed ID: 36248870 [TBL] [Abstract][Full Text] [Related]
5. Wilms' tumor gene 1 transcript levels in leukapheresis of peripheral blood hematopoietic cells predict relapse risk in patients autografted for acute myeloid leukemia. Messina C; Candoni A; Carrabba MG; Tresoldi C; Sala E; Tassara M; Crippa A; Peccatori J; Assanelli A; Gattillo S; Bellio L; Fanin R; Ciceri F; Bernardi M Biol Blood Marrow Transplant; 2014 Oct; 20(10):1586-91. PubMed ID: 24954546 [TBL] [Abstract][Full Text] [Related]
6. Droplet digital PCR for the simultaneous analysis of minimal residual disease and hematopoietic chimerism after allogeneic cell transplantation. Waterhouse M; Pfeifer D; Duque-Afonso J; Follo M; Duyster J; Depner M; Bertz H; Finke J Clin Chem Lab Med; 2019 Apr; 57(5):641-647. PubMed ID: 30457973 [TBL] [Abstract][Full Text] [Related]
7. WT1 Measurable Residual Disease Assay in Patients With Acute Myeloid Leukemia Who Underwent Allogeneic Hematopoietic Stem Cell Transplantation: Optimal Time Points, Thresholds, and Candidates. Cho BS; Min GJ; Park SS; Shin SH; Yahng SA; Jeon YW; Yoon JH; Lee SE; Eom KS; Kim YJ; Lee S; Min CK; Cho SG; Kim DW; Lee JW; Kim M; Kim Y; Kim HJ Biol Blood Marrow Transplant; 2019 Oct; 25(10):1925-1932. PubMed ID: 31173897 [TBL] [Abstract][Full Text] [Related]
8. Bone Marrow WT1 Levels in Allogeneic Hematopoietic Stem Cell Transplantation for Acute Myelogenous Leukemia and Myelodysplasia: Clinically Relevant Time Points and 100 Copies Threshold Value. Nomdedéu JF; Esquirol A; Carricondo M; Pratcorona M; Hoyos M; Garrido A; Rubio M; Bussaglia E; García-Cadenas I; Estivill C; Brunet S; Martino R; Sierra J Biol Blood Marrow Transplant; 2018 Jan; 24(1):55-63. PubMed ID: 28939453 [TBL] [Abstract][Full Text] [Related]
9. Minimal residual disease monitoring and preemptive immunotherapy in myelodysplastic syndrome after allogeneic hematopoietic stem cell transplantation. Mo XD; Qin YZ; Zhang XH; Xu LP; Wang Y; Yan CH; Chen H; Chen YH; Han W; Wang FR; Wang JZ; Liu KY; Huang XJ Ann Hematol; 2016 Aug; 95(8):1233-40. PubMed ID: 27302479 [TBL] [Abstract][Full Text] [Related]
10. Measurable residual disease, conditioning regimen intensity, and age predict outcome of allogeneic hematopoietic cell transplantation for acute myeloid leukemia in first remission: A registry analysis of 2292 patients by the Acute Leukemia Working Party European Society of Blood and Marrow Transplantation. Gilleece MH; Labopin M; Yakoub-Agha I; Volin L; Socié G; Ljungman P; Huynh A; Deconinck E; Wu D; Bourhis JH; Cahn JY; Polge E; Mohty M; Savani BN; Nagler A Am J Hematol; 2018 Sep; 93(9):1142-1152. PubMed ID: 29981272 [TBL] [Abstract][Full Text] [Related]
12. Minimal residual disease (MRD) positivity at allogeneic hematopoietic cell transplantation, not the quantity of MRD, is a risk factor for relapse of Philadelphia chromosome-positive acute lymphoblastic leukemia. Akahoshi Y; Arai Y; Nishiwaki S; Mizuta S; Marumo A; Uchida N; Kanda Y; Sakai H; Takada S; Fukuda T; Fujisawa S; Ashida T; Tanaka J; Atsuta Y; Kako S Int J Hematol; 2021 Jun; 113(6):832-839. PubMed ID: 33570732 [TBL] [Abstract][Full Text] [Related]
13. Prognostic impact of pretransplant measurable residual disease assessed by peripheral blood WT1-mRNA expression in patients with AML and MDS. Rautenberg C; Lauseker M; Kaivers J; Jäger P; Fischermanns C; Pechtel S; Haas R; Kobbe G; Germing U; Schroeder T Eur J Haematol; 2021 Aug; 107(2):283-292. PubMed ID: 33987857 [TBL] [Abstract][Full Text] [Related]
14. Application of a digital PCR method for WT1 to myeloid neoplasms in CR and deep ELN WT1 molecular response (< 10 copies). Bussaglia E; Pratcorona M; Carricondo M; Sansegundo L; Rubio MA; Monter A; Brell A; Badell I; Esteve J; Arnan M; Talarn C; Tormo M; García A; Vall-Llovera F; Ortin X; Pedro C; Bargay J; Brunet S; Sierra J; Nomdedéu J Ann Hematol; 2020 Apr; 99(4):765-772. PubMed ID: 32062741 [TBL] [Abstract][Full Text] [Related]
15. Comparison of minimal residual disease (MRD) monitoring by WT1 quantification between childhood acute myeloid leukemia and acute lymphoblastic leukemia. Zhang R; Yang JY; Sun HQ; Jia H; Liao J; Shi YJ; Li G Eur Rev Med Pharmacol Sci; 2015; 19(14):2679-88. PubMed ID: 26221900 [TBL] [Abstract][Full Text] [Related]